

FluCov Influenza Activity Report #13


19 February 2024

Take home: continued elevated influenza activity in the Northern Hemisphere


- North America and Europe: Influenza activity remains elevated with moderate to high activity in many U.S. states. In Europe, a mixed activity pattern was observed. Although influenza activity decreased in many countries (Denmark, France, Germany, Italy, Spain, UK), it continues to vary from low activity in Italy and Spain and very high activity in France.
- Asia: Influenza overall positivity rate continued to decrease in China, but remained elevated, with moderate activity reported in Northern China and medium activity reported in Southern China.
- Circulating virus: While A/H3 and B/Victoria have predominated globally and in China, A/H1N1pdm09 has dominated circulation in most of the Northern Hemisphere. Presently, there are no documented cases of B-Yamagata
- Vaccine match: Early indicators in the US suggest good vaccine match. France reports good match with A/H1N1pdm09, but mismatch in some percentage of A/H3 viruses.
- Influenza Viruses of Pandemic Potential: A fatal case of a coinfection of avian influenza A(H10N5) and seasonal influenza A(H3N2) was reported in a 63-year-old woman in China on 27 January 2024. This is the first human infection with A(H10N5) reported globally. In Cambodia, a 16-year-old boy with no respiratory symptoms tested positive for influenza A(H5N1), after his younger brother passed away from the same virus.
- COVID hospitalizations: Are decreasing in Italy, the Netherlands and the US, after a peak around the end of 2023.


Positive Influenza tests (%)

Note: France, Germany, Italy and UK positivity rate graph was last updated week 04/2024.




Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]





Weekly COVID-19 hospital admissions



(England, Italy, the Netherlands, US – admissions/1,000,000)

Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen.

Data sources & details

China:China CDCUS:FluView (Clinical Laboratories)NL & Spain:ERVISSDK:WHO FluNET (non-sentinel)All others:WHO FluNet (sentinel)COVID:Our World in Data

A Nivel publication

FluCov team: Bronke Boudewijns, Susanne Heemskerk, Marco Del Riccio, Saverio Caini, John Paget. FluCov Influenza Activity Report #13: 19 February 2024. Netherlands, Utrecht: Nivel, 2024

Websites for more information

Project Website: <u>https://www.nivel.nl/en/flucov</u> FluCoV Dashboard: <u>https://www.nivel.nl/en/flucov-dashboard</u>

Funding

The Nivel FluCov project is funded by Sanofi